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Polycystic ovarian syndrome (PCOS) ovaries are characterized by increased angiogenesis and hypervascularity. While
angiopoietin-1 (Ang-1) and its antagonist, angiopoietin-2 (Ang-2), are essential for ovarian function and
angiogenesis, the levels of Ang-1 and Ang-2 in PCOS are unknown. This was a prospective cohort study of 14 PCOS
women and 14 matched controls undergoing controlled ovarian stimulation (COS). Serum was collected on day 3,
hCG and retrieval days. Follicular fluid (FF) was collected on retrieval day. Serum Ang-1 and Ang-2 levels were
constant throughout COS, but serum Ang-1 levels were increased at all time points in PCOS women compared
with controls (p < 0.05). No differences between groups were found in serum Ang-2 levels or FF Ang-1 levels.
However, FF Ang-2 levels were increased almost 2-fold in PCOS women compared with controls (p < 0.01), and
correlated positively with number of oocytes retrieved (r = 0.65, p < 0.0001). This study is the first to provide
evidence of an alteration in the Ang-1/Ang-2 system in PCOS women. The biological role of Ang-2 in promoting
capillary leakage, the increased Ang-2 FF level in PCOS, and its correlation with number of oocytes suggest that
Ang-2 may play an important role in the increased risk of ovarian hyperstimulation in PCOS.
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Polycystic ovarian syndrome (PCOS) affects between 5-7%
of reproductive age women in Western societies. It is
characterized by anovulatory infertility, hyperandrogen-
ism, and polycystic ovaries [1,2]. In addition, women with
PCOS are also at an increased risk of pregnancy complica-
tions, obesity, hyperlipidemia, insulin resistance, type II
diabetes, and possibly cardiovascular disease [1,2].
Angiogenesis, blood vessel stabilization and regression
within the ovary are critical components of the menstrual
cycle [3]. Two of the most important classes of angiogenic
factors, vascular endothelial growth factors (VEGFs) and
the angiopoietins, are expressed in the ovary and regulate
angiogenesis in regular follicular growth, ovulation, and
the subsequent development and regression of the corpus* Correspondence: resheft@gmail.com
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stated.luteum [4-7]. Ovaries of PCOS women are characterized
by increased ovarian mass, supported by new blood vessel
proliferation in the stroma and theca [8,9]. Consistent
with increased angiogenesis, several studies have demon-
strated increased expression of angiogenic growth factors
in PCOS. VEGF has been shown to be upregulated in
ovarian tissue of PCOS women [8] while both VEGF and
basic fibroblast growth factor (bFGF) have been reported to
be increased in serum and follicular fluid of PCOS women
[9-11]. Moreover, soluble VEGF receptor-1 (sVEGFR-1), the
circulating receptor for VEGF, has been shown to be de-
creased in serum of PCOS women undergoing controlled
ovarian stimulation, contributing to increased VEGF bio-
availability [12]. Taken together, these data suggest that
PCOS patients have an angiogenic imbalance leading to a
pro-angiogenic profile.
VEGFs and angiopoietins work in concert to control
blood vessel formation, stabilization and regression [13].
Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) act
on vascular endothelial cells via the same tyrosine kinaseThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Patient clinical data
PCOS Non-PCOS P value
Age (years) 30.1 ± 4.4 30.8 ± 3.7 NS
Body mass index (Kg/m2) 25.5 ± 5.6 24.9 ± 3.9 NS
Serum AMH (ng/ml) 8.0 ± 6.5 3.1 ± 1.5 0.003
Day 3 FSH (mIU/ml) 5.2 ± 1.9 6.0 ± 2.7 NS
Total gonadotropin dose (IU) 2057 ± 868 2767 ± 1786 NS
Estrogen on day of hCG (pg/ml) 2819 ± 1158 2898 ± 860 NS
No. of aspirated oocytes 17.4 ± 10.5 12.6 ± 7.2 NS
OHSS (%) 3/14 (21.4) 0/14 (0) NS
Note: PCOS, polycystic ovarian syndrome; OHSS, ovarian hyperstimulation
syndrome; NS, not significant; values are mean ± standard deviation. P-value < 0.05
was considered statistically significant.
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lowing receptor binding. Ang-1 recruits and interacts
with perivascular smooth muscle cells (pericytes) stabil-
izing the neovessels formed by the action of VEGF [14].
In contrast, Ang-2 is a natural antagonist for Ang-1 and
plays a role in loosening the support of extracellular cell
matrix and destabilization of existing blood vessels by
antagonizing the action of Ang-1 [15]. It is thought that
in the presence of VEGF, the action of Ang-2 promotes
angiogenesis by allowing endothelial cell proliferation
and migration, whereas in the absence of VEGF, Ang-2
signal blocks the recruitment of pericytes, leading to ves-
sel destabilization and regression [13,16]. Ang-1, Ang-2
and their Tie-2 receptor are expressed in the ovarian fol-
licle and corpus luteum and have been shown to play a
critical role in follicular growth, ovulation and corpus
luteum development in both primates and humans [4-6].
In fact, disruption of the Ang-1/Ang-2 balance by intra-
follicular Ang-2 injection prevents follicular angiogen-
esis, ovulation and subsequent corpus luteum formation
in primates [17].
Recently, Ang-1 and Ang-2 serum and follicular fluid
levels have been reported in humans during controlled
ovarian stimulation [18]. In addition, serum Ang-2 levels
in non-stimulated women were not found to be different
between PCOS and matched controls [19]. However, des-
pite evidence suggesting an important role for angiopoie-
tins in ovarian angiogenesis, their levels and dynamics
have not been previously investigated in PCOS during
controlled ovarian stimulation. Previously, we reported
that the proangiogenic transforming growth factor-β
(TGF-β) is increased while its soluble endoglin receptor is
decreased in serum of PCOS women, contributing to
greater TGF-β bioavailability and proangiogenic state [20].
We hypothesized that Ang-1 and Ang-2 levels may be in-
creased in PCOS, consistent with increased angiogenesis
and hypervascularity observed in PCOS ovaries. Accord-
ingly, we wished to investigate Ang-1 and Ang-2 levels
and temporal expression patterns in serum and follicular
fluid of PCOS women as compared to non-PCOS control
women during controlled ovarian stimulation in our pre-
viously described study population [20].
Methods
Study subjects
We prospectively enrolled 14 PCOS women from women
undergoing controlled ovarian stimulation (COS) in prep-
aration for IVF or ICSI as previously described [20]. Diag-
nosis of PCOS was made according to the Rotterdam
consensus [21]. All 14 PCOS women had oligo- or amen-
orrhea and at least 12 follicles 2-9 mm in diameter per
ovary. Ten of the women had hyperandrogenemia and/or
hyperandrogenism, and four had normal serum androgen
levels and no clinical hyperandrogenism. Secondary causesof androgen excess and anovulation were excluded. The
indications for COS in the PCOS group were male factor
(7 women), ovulatory dysfunction after failed superovula-
tion induction and intrauterine inseminations (4 women)
and tubal factor (3 women). Fourteen non-PCOS control
women undergoing COS in preparation for IVF or ICSI
were matched to PCOS women by age, BMI and use of
GnRH agonist/antagonist prior to enrollment. Inclusion
criteria for control non-PCOS women were normal ultra-
sonic ovarian morphology, normal ovulatory cycles and
no endocrine abnormalities. Inclusion criteria for all study
women were ages between 20–38, adequate visualization
of ovaries on transvaginal ultrasound and no hormonal
treatment i.e. OCPs. Exclusion criteria were diminished
ovarian reserve or endometriosis. The indications for COS
in the control group were male factor (9 women) or tubal
factor infertility (5 women). Patient clinical data is given
in Table 1. This study was approved by the Maimonides
Medical Center institutional review board. Informed con-
sent was obtained from all participating women.
Women were treated using a stimulation protocol which
included either down regulation using a GnRH agonist in
a long protocol (n=8 for each group) or a GnRH antagon-
ist to prevent premature ovulation (n=6 for each group).
Ovarian stimulation was performed using a combination
of recombinant FSH and HMG. The standard stimulation
protocol was modified when there was risk of ovarian
hyperstimulation or previous history of poor response.
Follicular monitoring by ultrasound and blood sampling
for estradiol levels were performed every 1–3 days. After
the first 3–5 treatment days, the daily dose could be ad-
justed based on the follicular development and estradiol
levels. When at least six follicles with a diameter of
16 mm were detected, either 5,000 or 10,000 IU hCG was
administered, depending on the estimated risk for hyper-
stimulation. Oocytes were retrieved under transvaginal
sonographic guided needle puncture 35 hours following
hCG administration.
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Blood samples were obtained by venipuncture on cycle
day 3, day of hCG administration and day of oocyte re-
trieval. After collection, the blood samples were allowed
to clot at room temperature for 30 min, followed by cen-
trifugation at 1200 rpm for 10 min. Serum was stored in
aliquots at −80°C until assayed. For follicular fluid collec-
tion, follicles with a diameter of >16 mm were aspirated.
Only the first clear follicular fluid aspirate associated with
the presence of an oocyte, without blood or flushing solu-
tion, was used for analysis. After removal of the oocyte,
the fluid was centrifuged at 1200 rpm for 10 min to re-
move granulosa cells and debris. The supernatant was di-
vided into aliquots and stored at −80°C until assayed.
Ang-1, Ang-2 and AMH ELISA assays
Ang-1 and Ang-2 concentrations of serum and follicular
fluid samples were determined by ELISA according to
the manufacturer’s protocols (R&D, Minneapolis, MN),
having a sensitivity of 62.5 pg/mL and 46.9 pg/mL, re-
spectively. The intra- and inter-assay coefficients of vari-
ation for Ang-1 and Ang-2 ELISAs were 2.4% and 5.5%,
and 6.5% and 9.1%, respectively. AMH concentration of
serum and follicular fluid samples was determined ac-
cording to the manufacturer’s protocols (Beckman and
Coulter, Brea, CA). The assay sensitivity was 0.16 ng/ml.
The intra- and inter-assay coefficients of variation were
4.3% and 7.4%, respectively. All assays were performed
in duplicate.
Statistics
A power analysis powered for a two-tailed t-test was car-
ried out prior to subject enrollment to determine the mini-
mum required sample sizes needed to detect a 1.5-fold
(assumed) statistically significant difference in growth fac-
tor between cases (PCOS) and controls. The required level
of significance was at least 95% (α=0.05), and the required
power of the test was at least 90% (β=0.10). Based on this
calculation the required sample sizes were n = 14 for each
group. Data were analyzed by Student’s t-test or the
Mann–Whitney test, as appropriate. Results are expressed
as mean ± standard error of the mean (SEM). Correlations
between angiopoietins and number of oocytes retrieved
were performed using Pearson correlation tests. SigmaStat
(SPSS Science, Chicago, IL) was used for statistical analysis.
All significance tests were two-tailed and P-value < 0.05
was considered to be statistically significant.
Results
There were no differences between PCOS and non-PCOS
women in terms of age, body mass index, day 3 FSH, total
amount of gonadotropins administered, estrogen levels on
day of hCG administration and number of aspirated oo-
cytes (Table 1). In contrast, as expected, PCOS womenhad a significantly higher serum AMH level than the non-
PCOS control group (8.0 ± 6.5 ng/ml vs. 3.1 ± 1.5 ng/ml,
p = 0.003) (Table 1). In addition, 3 of 14 PCOS women de-
veloped mild OHSS whereas no OHSS was noted in the
non-PCOS group.
Ang-1 serum levels did not change throughout con-
trolled ovarian stimulation in either PCOS or control
women (Figure 1A). However, Ang-1 serum levels were
significantly greater in PCOS women compared with
non-PCOS controls at all three time points, on day 3
(43.7 ± 2.6 ng/ml vs. 30.9 ± 4.3 ng/ml, p = 0.02), day of
hCG administration (47.4 ± 3.1 ng/ml vs. 34.2 ± 4.5 ng/ml,
p = 0.02), and day of oocyte retrieval (49.0 ± 4.3 ng/ml vs.
33.9 ± 6.0 ng/ml, p = 0.04) (Figure 1A). No differences be-
tween groups were observed in follicular fluid Ang-1 levels
(Figure 1B). In addition, no correlation was found between
serum or follicular fluid Ang-1 levels and number of oo-
cytes retrieved (data not shown).
Similarly to Ang-1, Ang-2 serum levels were constant
throughout controlled ovarian stimulation in either PCOS
or non-PCOS women (Figure 2A). In contrast to Ang-1
serum levels, Ang-2 serum levels were not different be-
tween the two groups on day 3, day of hCG or day of oo-
cyte retrieval (Figure 2A). Furthermore, follicular fluid
Ang-2 levels were 1.9-fold greater in PCOS women com-
pared with non-PCOS controls (19.6 ± 2.6 ng/ml vs. 10.5 ±
1.2 ng/ml, p < 0.01) (Figure 2B). Moreover, Ang-2 levels in
follicular fluid were found to positively correlate with the
number of oocytes retrieved in both PCOS and non-PCOS
groups (r = 0.65, p < 0.0001) (Figure 3). No correlation was
noted between serum Ang-2 levels and number of oocytes
retrieved (data not shown).
Ang-1 concentration was markedly higher in serum
compared with follicular fluid, with serum/follicular fluid
ratios ranging from 102–114 and 77–85 in PCOS and
non-PCOS groups, respectively (data not shown). Con-
versely, Ang-2 levels were greater in follicular fluid than
serum, with a reversal in serum/follicular fluid ratio, ran-
ging from 0.06-0.07 and 0.11-0.12 in PCOS and non-
PCOS groups, respectively (data not shown). Since Ang-1
and Ang-2 exert opposing actions, their ratio may provide
insight into the angiogenic status, and particularly the pro-
pensity for vessel stabilization versus regression. The Ang-
1/Ang-2 ratio in serum of PCOS women was significantly
increased compared with non-PCOS women at all three
measured time points, on day 3 (39.7 ± 2.3 vs. 24.9 ± 2.6,
p = 0.02), day of hCG administration (39.2 ± 2.9 vs. 28.5 ±
1.7, p = 0.04), and day of oocyte retrieval (38.2 ± 3.1 vs.
27.3 ± 1.9, p = 0.01) (Table 2). Remarkably, the Ang-1/
Ang-2 ratio was reversed in follicular fluid compared with
serum, due to lower Ang-1 and higher Ang-2 levels in fol-
licular fluid compared with serum. In addition, the Ang-1/
Ang-2 ratio was significantly decreased in follicular fluid
of PCOS compared with non-PCOS women (0.02 ± 0.004
Figure 1 Ang-1 concentration in (A) serum (ng/ml) and (B) follicular fluid (ng/ml) of PCOS (polycystic ovarian syndrome) and non-PCOS
women undergoing controlled ovarian stimulation. Serum Ang-1 levels were consistently increased in PCOS compared with non-PCOS
women throughout controlled ovarian stimulation, while no differences between groups were observed in follicular fluid. Data are presented as
mean ± SEM. *p < 0.05 for PCOS vs. non-PCOS women.
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licular fluid Ang-2 levels in the PCOS group (Table 2).Discussion
This is the first study to report levels and dynamics of
Ang-1 and Ang-2 in PCOS women during the course of
controlled ovarian stimulation. Our data demonstrate
that serum Ang-1 and Ang-2 levels remained unchanged
during controlled ovarian stimulation in both PCOS and
non-PCOS women. However, Ang-1 levels were found to
be increased in serum of PCOS compared with non-PCOS
women throughout controlled ovarian stimulation, while
Ang-2 was increased in follicular fluid of PCOS women
compared with controls. Consequently, Ang-1/Ang-2 ratio
was increased in serum but decreased in follicular fluid of
PCOS relative to non-PCOS women. Moreover, this study
is the first to report a correlation between follicular fluid
Ang-2 levels and number of oocytes retrieved, a findingFigure 2 Ang-2 concentration in (A) serum (ng/ml) and (B) follicular f
women undergoing controlled ovarian stimulation. Follicular fluid Ang
No differences between groups were noted in serum Ang-2 levels. Data arwhich may have important clinical implications for IVF
and ovarian hyperstimulation syndrome (OHSS).
In the present study, serum Ang-1 levels were unchanged
during controlled ovarian stimulation but were consistently
increased in PCOS women compared with non-PCOS con-
trols. Serum Ang-2 levels were also unchanged throughout
controlled ovarian stimulation. However, in contrast to
Ang-1, no differences were noted in serum Ang-2 levels be-
tween PCOS and non-PCOS women. Our data are consist-
ent with a previous report that did not find a difference
in serum Ang-2 levels between unstimulated PCOS and
matched non-PCOS women [19]. Elevated serum Ang-1 in
PCOS in our study is also consistent with several previous
reports indicating increased angiogenesis in PCOS women.
VEGF has been shown to be increased in serum [9,11] and
ovarian tissue [8] of PCOS women compared with non-
PCOS controls. Moreover, VEGF and basic fibroblast
growth factor (bFGF) levels have been shown to be greater
in serum and follicular fluid of PCOS women compared toluid (ng/ml) of PCOS (polycystic ovarian syndrome) and non-PCOS
-2 levels were increased in PCOS compared with non-PCOS women.
e presented as mean ± SEM. *p < 0.01 for PCOS vs. non-PCOS women.
Figure 3 Correlation between follicular fluid Ang-2 levels and
total number of oocytes retrieved in women with PCOS and
non-PCOS controls, demonstrating a significant positive
correlation in both groups (r = 0.65, p < 0.0001).
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an angiogenic dysregulation promoting angiogenesis. Ang-1
is widely expressed mainly by smooth muscle cells, adventi-
tial cells and endothelial cells of the vasculature [22]. Since
the concentration of Ang-1 is much greater in serum com-
pared to follicular fluid, the systemic vascular bed is the
likely source of increased circulating Ang-1 levels in PCOS
and not the ovary.
In the current study, Ang-1 serum levels during con-
trolled ovarian stimulation were 77 to 114-fold greater
than follicular fluid levels. In contrast, Ang-2 serum
levels during controlled ovarian stimulation were 8 to
16-fold lower than follicular fluid levels. Accordingly,
the Ang-1/Ang-2 ratio in serum ranged from 24.9 to
39.7, while Ang-1/Ang-2 ratio in follicular fluid was re-
versed, ranging from 0.02 to 0.04. Follicular fluid is the
product of diffusion of blood constituents across the
blood-follicle barrier and of molecules secreted by gran-
ulosa and theca cells. Our data suggest that the local
ovarian angiopoietin milieu is not reflected in the blood-
stream and that Ang-2 is produced in large amount locally
within the ovary and is the predominant angiopoietin in
this microenvironment. The great difference in Ang-1Table 2 Ang-1/Ang-2 ratio in serum and follicular fluid of
PCOS and non-PCOS women
Sample PCOS Non-PCOS P value
Serum day 3 39.7 ± 2.3 24.9 ± 2.6 0.02
Serum day of hCG 39.2 ± 2.9 28.5 ± 1.7 0.04
Serum day of retrieval 38.2 ± 3.1 27.3 ± 1.9 0.01
Follicular fluid 0.02 ± 0.004 0.04 ± 0.006 0.002
Note: PCOS, polycystic ovarian syndrome; Data are presented as mean ± S.E.M.concentration between serum and follicular fluid may be
explained by the propensity of Ang-1 to incorporate into
and be sequestered by extracellular matrix, making it un-
likely to diffuse to distant organs, in contrast to Ang-2
[23]. In addition, Ang-1, a 70 kDa molecule, predominantly
exists in high-order multimers [24], which may be specu-
lated to limit its diffusion capacity across the blood-follicle
barrier. Our data support earlier findings by Hurliman
et al. who reported Ang-1/Ang-2 ratios in serum and fol-
licular fluid during controlled ovarian stimulation in a
population of oocyte donors [18]. They found similar Ang-
1/Ang-2 ratios in serum and follicular fluid to the ones
reported in our study. In addition, consistent with our re-
sults, Hurliman et al. did not find changes in serum Ang-1
or Ang-2 levels throughout controlled ovarian stimulation
or menstrual cycle [18]. In contrast to the lack of variation
in Ang-1 and Ang-2 levels in serum throughout follicu-
lar growth, selection, ovulation and luteinization, marked
changes in Ang-1 and Ang-2 levels occur in the ovaries
during the human menstrual cycle [5,6], further supporting
the notion that local ovarian angiopoietin levels are not
reflected in the bloodstream. Moreover, the lack of change
in Ang-1 and Ang-2 serum levels following oophorectomy
is consistent with this premise [18].
Our data and that of Hurliman et al. [18] showed that
following controlled ovarian stimulation Ang-1/Ang-2
ratio in follicular fluid is very low, consistent with ovar-
ian predominance of Ang-2 over Ang-1 in the periovula-
tory period. Evidence from several studies is consistent
with this hypothesis. Wulff et al. have reported that ratio
of Ang-2/Ang-1 ovarian mRNA expression ranges from 2
to 47-fold during the menstrual cycle, reaching the great-
est ratio following hCG injection [5]. Similarly, Sugino
et al. have shown that ovarian Ang-2 mRNA and protein
levels are significantly greater than Ang-1 throughout the
menstrual cycle [6]. Moreover, they showed that ovarian
Ang-2 levels are greatest during the follicular and early lu-
teal phase, while Ang-1 levels are lowest during the early
luteal phase [6]. The proposed Ang-2 predominance in
the ovary in the periovulatory period may have important
implications for the pathogenesis of ovarian hyperstimula-
tion (OHSS).
VEGF is a key mediator of OHSS and is found to be
elevated in the circulation [25,26], follicular fluid [27] and
ascites fluid [28] of patients developing this syndrome. Its
dysregulation in PCOS has been suggested to contribute to
the increased risk of OHSS seen in these patients [29].
VEGF is thought to be secreted by the ovarian endothelial
and granulosa cells and promote vascular permeability lead-
ing to significant fluid extravasation in OHSS [29]. The
agonist Ang-1 and its antagonist Ang-2 are also known to
influence vascular permeability in the context of angiogen-
esis. Ang-1 stabilizes newly formed vessels and reduces ca-
pillary permeability and leakage [14,30]. In contrast, the
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and lead to vessel destabilization and increased permeability
[31,32]. In the current study, PCOS women had signifi-
cantly greater Ang-2 levels in follicular fluid than non-
PCOS women following controlled ovarian stimulation.
This resulted in lower Ang-1/Ang-2 follicular fluid ratio in
PCOS compared with non-PCOS women, indicating that
the follicular microvasculature in PCOS may be more
prone to fluid leakage. These data suggest that the increased
risk for OHSS development in PCOS women may be ex-
plained, at least in part, by Ang-2 overactivity. Our data
demonstrating a strong correlation between follicular fluid
Ang-2 levels and the number of oocytes retrieved i.e. ovar-
ian stimulation provide further support for this notion. In
our study, 3 of 14 PCOS women developed mild OHSS
while no OHSS was noted in the control group. Ang-1 and
Ang-2 serum and follicular fluid levels were not different
between patients who developed OHSS compared to those
who did not (data not shown). However, our study is lim-
ited by small number of patients and was not powered for
such a comparison. Future studies are warranted to evaluate
the potential role of Ang-2 in OHSS pathogenesis and
examine its utility as a predictor for early and/or late OHSS.
Such studies may pave the way for better monitoring
and individualization of ovarian stimulation for those
patients who are at highest risk of OHSS, in addition to
potential development of new biological interventions
targeting the angiopoietin system for prevention and/or
treatment of OHSS.
In conclusion, this is the first study to characterize Ang-
1 and Ang-2 levels in PCOS during controlled ovarian
stimulation and to provide evidence of an alteration in the
Ang-1/Ang-2 system in PCOS women compared with
control women. The concentrations of serum Ang-1 and
Ang-2 are relatively constant throughout controlled ovar-
ian stimulation, but serum Ang-1 levels are consistently
increased in PCOS women compared with controls. In
addition, the predominance of Ang-2 over Ang-1 in the
ovary, increased Ang-2 follicular fluid levels in PCOS, and
the correlation of follicular fluid Ang-2 levels with number
of oocytes retrieved suggest a potential role for Ang-2 in
the angiogenic dysregulation seen in PCOS women, and
their predisposition for OHSS development. Further stud-
ies are indicated to explore these possibilities.
Competing interest
D.B.S. receives royalties from a licensing agreement between UMDNJ/MGH
and Beckman Coulter for the use of MIS/AMH in determining ovarian
reserve. R.T., R.V.G. and H.E.M have nothing to declare.
Authors’ contribution
RT conceived and designed the study, performed the ELISA experiments and
statistical analysis, and drafted the manuscript. DBS designed the study and
edited the manuscript. RVG edited the manuscript. HEM helped with study
design and performed patient sample collection. All authors read and
approved the final manuscript.Acknowledgements
The authors thank Dr. Howard Minkoff for scientific advice. We thank Dr. Dan
Eshel for using his lab facilities and Dr. Theodore Muth for microplate ELISA
reader. We also thank Cindy Ammirabile for her help with patient
recruitment. This work was supported by a grant from Maimonides Medical
Center Research and Development Foundation (RT, DBS). The work was
presented in part on October 24, 2012 at the 68th annual American Society
of Reproductive Medicine (ASRM) meeting, San-Diego, CA.
Received: 8 September 2013 Accepted: 21 October 2013
Published: 24 October 2013
References
1. Padmanabhan V: Polycystic ovary syndrome–“A riddle wrapped in a
mystery inside an enigma”. J Clin Endocrinol Metab 2009, 94(6):1883–1885.
2. Qiao J, Feng HL: Extra- and intra-ovarian factors in polycystic ovary
syndrome: impact on oocyte maturation and embryo developmental
competence. Hum Reprod Update 2011, 17(1):17–33.
3. Fraser HM, Wulff C: Angiogenesis in the corpus luteum. Reprod Biol
Endocrinol 2003, 1:88.
4. Hazzard TM, Christenson LK, Stouffer RL: Changes in expression of vascular
endothelial growth factor and angiopoietin-1 and −2 in the macaque
corpus luteum during the menstrual cycle. Mol Hum Reprod 2000,
6(11):993–998.
5. Wulff C, Wilson H, Largue P, Duncan WC, Armstrong DG, Fraser HM:
Angiogenesis in the human corpus luteum: localization and changes in
angiopoietins, tie-2, and vascular endothelial growth factor messenger
ribonucleic acid. J Clin Endocrinol Metab 2000, 85(11):4302–4309.
6. Sugino N, Suzuki T, Sakata A, Miwa I, Asada H, Taketani T, Yamagata Y,
Tamura H: Angiogenesis in the human corpus luteum: changes in
expression of angiopoietins in the corpus luteum throughout the
menstrual cycle and in early pregnancy. J Clin Endocrinol Metab 2005,
90(11):6141–6148.
7. Geva E, Jaffe RB: Role of vascular endothelial growth factor in ovarian
physiology and pathology. Fertil Steril 2000, 74(3):429–438.
8. Ferrara N, Frantz G, LeCouter J, Dillard-Telm L, Pham T, Draksharapu A,
Giordano T, Peale F: Differential expression of the angiogenic factor
genes vascular endothelial growth factor (VEGF) and endocrine gland-
derived VEGF in normal and polycystic human ovaries. Am J Pathol 2003,
162(6):1881–1893.
9. Agrawal R, Sladkevicius P, Engmann L, Conway GS, Payne NN, Bekis J, Tan SL,
Campbell S, Jacobs HS: Serum vascular endothelial growth factor
concentrations and ovarian stromal blood flow are increased in women
with polycystic ovaries. Hum Reprod 1998, 13(3):651–655.
10. Artini PG, Monti M, Matteucci C, Valentino V, Cristello F, Genazzani AR:
Vascular endothelial growth factor and basic fibroblast growth factor in
polycystic ovary syndrome during controlled ovarian hyperstimulation.
Gynecol Endocrinol 2006, 22(8):465–470.
11. Amin AF, Abd el-Aal DE, Darwish AM, Meki AR: Evaluation of the impact of
laparoscopic ovarian drilling on Doppler indices of ovarian stromal
blood flow, serum vascular endothelial growth factor, and insulin-like
growth factor-1 in women with polycystic ovary syndrome. Fertil Steril
2003, 79(4):938–941.
12. Artini PG, Ruggiero M, Parisen Toldin MR, Monteleone P, Monti M, Cela V,
Genazzani AR: Vascular endothelial growth factor and its soluble receptor
in patients with polycystic ovary syndrome undergoing IVF.
Hum Fertil (Camb) 2009, 12(1):40–44.
13. Carmeliet P: Angiogenesis in health and disease. Nat Med 2003, 9(6):653–660.
14. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J,
McDonald DM, Yancopoulos GD: Angiopoietin-1 protects the adult
vasculature against plasma leakage. Nat Med 2000, 6(4):460–463.
15. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C,
Compton D, McClain J, Aldrich TH, Papadopoulos N, et al: Angiopoietin-2, a
natural antagonist for Tie2 that disrupts in vivo angiogenesis.
Science 1997, 277(5322):55–60.
16. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J:
Vascular-specific growth factors and blood vessel formation. Nature 2000,
407(6801):242–248.
17. Xu F, Stouffer RL: Local delivery of angiopoietin-2 into the preovulatory
follicle terminates the menstrual cycle in rhesus monkeys. Biol Reprod
2005, 72(6):1352–1358.
Tal et al. Vascular Cell 2013, 5:18 Page 7 of 7
http://www.vascularcell.com/content/5/1/1818. Hurliman AK, Speroff L, Stouffer RL, Patton PE, Lee A, Molskness TA:
Changes in circulating levels and ratios of angiopoietins during
pregnancy but not during the menstrual cycle and controlled ovarian
stimulation. Fertil Steril 2010, 93(5):1493–1499.
19. Sova H, Morin-Papunen L, Puistola U, Karihtala P: Distinctively low levels of
serum 8-hydroxydeoxyguanosine in women with polycystic ovary
syndrome. Fertil Steril 2010, 94(7):2670–2673.
20. Tal R, Seifer DB, Shohat-Tal A, Grazi RV, Malter HE: Transforming growth
factor-beta1 and its receptor soluble endoglin are altered in polycystic
ovary syndrome during controlled ovarian stimulation. Fertil Steril 2013,
100(2):538–543.
21. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group:
Revised 2003 consensus on diagnostic criteria and long-term health risks
related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19(1):41–47.
22. Mofarrahi M, Hussain SN: Expression and functional roles of angiopoietin-
2 in skeletal muscles. PLoS One 2011, 6(7):e22882.
23. Xu Y, Yu Q: Angiopoietin-1, unlike angiopoietin-2, is incorporated into
the extracellular matrix via its linker peptide region. J Biol Chem 2001,
276(37):34990–34998.
24. Procopio WN, Pelavin PI, Lee WM, Yeilding NM: Angiopoietin-1 and −2
coiled coil domains mediate distinct homo-oligomerization patterns, but
fibrinogen-like domains mediate ligand activity. J Biol Chem 1999,
274(42):30196–30201.
25. Pau E, Alonso-Muriel I, Gomez R, Novella E, Ruiz A, Garcia-Velasco JA, Simon C,
Pellicer A: Plasma levels of soluble vascular endothelial growth factor
receptor-1 may determine the onset of early and late ovarian
hyperstimulation syndrome. Hum Reprod 2006, 21(6):1453–1460.
26. Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohi J, Simon C: The
pathogenesis of ovarian hyperstimulation syndrome: in vivo studies
investigating the role of interleukin-1beta, interleukin-6, and vascular
endothelial growth factor. Fertil Steril 1999, 71(3):482–489.
27. Neulen J, Wenzel D, Hornig C, Wunsch E, Weissenborn U, Grunwald K,
Buttner R, Weich H: Poor responder-high responder: the importance of
soluble vascular endothelial growth factor receptor 1 in ovarian
stimulation protocols. Hum Reprod 2001, 16(4):621–626.
28. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV Jr, Connolly DT,
Robertson DM: Vascular endothelial growth factor as capillary permeability
agent in ovarian hyperstimulation syndrome. Lancet 1994, 344(8917):235–236.
29. Soares SR, Gomez R, Simon C, Garcia-Velasco JA, Pellicer A: Targeting the
vascular endothelial growth factor system to prevent ovarian
hyperstimulation syndrome. Hum Reprod Update 2008, 14(4):321–333.
30. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato
TN, Yancopoulos GD: Increased vascularization in mice overexpressing
angiopoietin-1. Science 1998, 282(5388):468–471.
31. Nourhaghighi N, Teichert-Kuliszewska K, Davis J, Stewart DJ, Nag S: Altered
expression of angiopoietins during blood–brain barrier breakdown and
angiogenesis. Lab Invest 2003, 83(8):1211–1222.
32. Roviezzo F, Tsigkos S, Kotanidou A, Bucci M, Brancaleone V, Cirino G,
Papapetropoulos A: Angiopoietin-2 causes inflammation in vivo by
promoting vascular leakage. J Pharmacol Exp Ther 2005, 314(2):738–744.
doi:10.1186/2045-824X-5-18
Cite this article as: Tal et al.: Angiopoietin-1 and angiopoietin-2 are
altered in polycystic ovarian syndrome (PCOS) during controlled ovarian
stimulation. Vascular Cell 2013 5:18.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
